Aggiornamento aziendale16 ott 2026ENOXB Appoints Joachim Kreuzburg as Independent Non-Executive DirectorOxford Biomedica plcCompany newsroom
Aggiornamento aziendale22 set 2026ENOxford Biomedica PLC Interim results for the six months ended 30 June 2026Oxford Biomedica plcCompany newsroom
Aggiornamento aziendale7 ago 2026ENHalf Year Trading Update and Notice of ResultsOxford Biomedica plcCompany newsroom
Aggiornamento aziendale16 lug 2026ENOXB Selected as GMP Manufacturing Partner to Support Manufacturing of Plowshare Therapies’ AAV Gene Therapy ProgrammeOxford Biomedica plcCompany newsroom
Aggiornamento aziendale8 mag 2026ENOXB to exhibit and present at the 30th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)Oxford Biomedica plcCompany newsroom
Aggiornamento aziendale13 apr 2026ENOXB launches fast-track offering for AAV and lentiviral vector platforms, accelerating viral vector development and manufactureOxford Biomedica plcCompany newsroom
Aggiornamento aziendale27 mar 2026ENOXB recognised as ‘Most Innovative CDMO (Cell & Gene)’ at 2026 CDMO Leadership AwardsOxford Biomedica plcCompany newsroom
Aggiornamento aziendale26 mar 2026ENPreliminary results for the year ended 31 December 2025Oxford Biomedica plcCompany newsroom
Aggiornamento aziendale18 mar 2026ENOXB enters into licensing agreement with Viral Vector Manufacturing Facility (VVMF), providing access to its AAV and LV viral vector platformsOxford Biomedica plcCompany newsroom
